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Objective: The present study aimed to analyze 219 notifications of suspected adverse reactions (AR) produced
by psychoactive medicaments (ARPM), notified by Brazilian psychiatrists, during a 3-month period (April
1999 up to September 2001).
Method: A notifying card for adverse reactions possibly produced by psychoactive medications was quarterly
sent to all psychiatrists affiliated to the Brazilian Association of Psychiatry. Once each notification, dully filled
in, was received, the possible adverse reaction was analyzed in order to verify the causality
Results: The psychiatrists classified as severe 50 of the ARPMs; 150 others were not considered as severe.
Among the severe ones there were 3 deaths, 12 life-threatening reactions, 26 ARPMs required or prolonged
hospitalization and 9 notifications described temporary disability of the patients. Among the medications,
antidepressants ranked first with 122 ARPMs being notified, followed by neuroleptics (46 ARPMs) and antiepiletic
medicaments (25 ARPMs). The three main organs and systems affected by the ARs were the Central Nervous
System with 102 ARs, skin and mucosa with 44 and gastrointestinal with 21 ARPMs.
Conclusion: Considering causality, i.e., the association between the medication and the described AR, 24 cases
were considered as Definite (with positive dechallenge and rechallenge, i.e., withdrawal and reintroduction of
the medication) and 134 other ARPMs were classified as Probable (only dechallenge positive; only with
medication withdrawal; rechallenge was not performed).
Adverse reaction to medicines. Pharmacovigilance. Psychoactive medicaments. Causality of adverse drug
reactions.
Objetivo: O presente estudo visou analisar 219 notificações de suspeita de reações adversas (RA) produzidas
por medicamentos psicoativos (RAMPs), preenchidas por médicos psiquiatras durante um período de três me-
ses (abril de 1995 a setembro de 2001).
Método: Uma ficha para notificação de reações adversas possivelmente produzidas por medicamentos psicoativos
era enviada a cada três meses para todos os médicos psiquiatras filiados à Associação Brasileira de Psiquiatria.
Uma vez recebida uma destas notificações, devidamente preenchida, a possível reação adversa era analisada
para verificação da causalidade.
Resultados: Os psiquiatras classificaram como sérias 50 das RAMPs; 150 outras foram consideradas não-
sérias. Entre as sérias houve três mortes, 12 relataram risco de vida, 26 RAMPs exigiram ou prolongaram
hospitalização e nove notificações descreveram invalidez temporária dos pacientes. Entre os medicamentos, os
antidepressivos ficaram em primeiro lugar, com 122 RAMPs notificadas, seguidos dos neurolépticos (46 RAMPs)
e anticonvulsivantes (25 RAMPs). Os três principais órgãos e sistemas afetados pelas ARs foram: Sistema
Nervoso Central, com 102 ARs, pele e mucosa, com 44, e gastrointestinal, com 21 RAMPs.
Conclusão: Considerando a causalidade, ou seja, a associação entre o medicamento e a RA descrita, em 24
casos, as RAMPs foram considerados Definidas (com “dechallenge” e “rechallenge” positivas; isto é, retirada e
reintrodução do medicamento) e 134 outras RAMPs foram classificadas como Prováveis (só “dechallenge”
positiva; só com a retirada do medicamento. A “rechallenge” não foi feita).
Reação adversa a medicamentos. Farmacovigilância. Medicamentos psicoativos. Causalidade de reações ad-
versas às drogas.
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Introduction
Psychoactive medications represent a sizeable part of the
medications used in Brazil. Thus, of 552.6 millions of prescrip-
tions in 2000, 74.9 millions (13.6%) were for psychoactive
medications (National Disease and Therapeutic Index-IMS
Health; December 2000-YTD). The prescriptions for these psy-
choactive medications were filled out, among others, by gen-
eral practitioners (29.7%), followed by psychiatrists (19.3%),
neurologists (9.5%), cardiologists (5.6%), and gynecologists/
obstetricians (4.1%), in that order (National Disease and Thera-
peutic Index–IMS Health; December 2000-YTD). Among the
psychoactive medications sold, benzodiazepines ranked first,
followed by antidepressants, but relevant amounts of
neuroleptics, antiepileptics and CNS stimulants (mostly am-
phetamine-like anorectics) were also used.
On the other hand, the psychoactive substances were not de-
void of toxicity; there were many reports of adverse reactions
(AR) induced by them, including severe ones, involving anti-
depressants,1-3 antiparkinsonian drugs,4,5 neuroleptics,6,7
anticonvulsants8,9 and benzodiazepines.10,11
Fatal reactions have been also reported for some psychoac-
tive substances.12
Needless to say that pharmacovigilance plays a capital role
to detect AR and consequently to protect the user population
from such accidents.13-15
In Brazil, unfortunately, pharmacovigilance is still in its
embrionary phase and there are no governmental reports on
the adverse events related to medications in general and, con-
sequently, to psychoactive substances in particular. Those facts
led the Department of Psychobiology of the Paulista Medical
School at the Federal University of São Paulo to organize a
national system to collect, directly from Brazilian psychiatrists,
spontaneous data on adverse reactions provoked by psychoac-
tive medications. This activity is known as PSIFAVI (Psico-
Farmaco-Vigilância, in Portuguese). This paper describes the
results obtained after 30 months of activity, from April 1999
(when the program started) up to September 2001.
Methods
From April 1999 up to September 2001, the 3,160 Brazilian
psychiatrists affiliated to the Brazilian Association of Psychia-
try received quarterly a yellow form called ‘Notification of a
Suspected Psychoactive Medication Adverse Reaction
(ARMP)’. Therefore, in the above period of time each psy-
chiatrist received 10 ARPMs; thus, 31,600 ARPMs were sent
in that 30-month period. In the same envelope, accompanying
each ARMP, it was also mailed a 4-page publication, called
PSIFAVI Bulletin, quarterly edited, containing news on adverse
reactions produced by psychoactive drugs either in Brazil (very
few) or abroad. The total number of Medical Doctors practic-
ing in Brazil is, according to the Federal Council of Medicine
(www.portalmedico.org.br), 284,800; therefore, the contacted
Brazilian psychiatrists represent 1.1% of that total.
The following procedure was adopted whenever a duly filled-
out ARMP was received from a psychiatrist:
• a PSIFAVI letter was sent acknowledging the reception of
the ARMP, accompanied by information (scientific
literature) on all known adverse reactions produced by the
involved psychoactive substance. In order to stimulate the
medical doctor to further collaboration he/she was offered,
free of charge, a one-year subscription of a Brazilian medical
journal (a list of which was enclosed to allow a choice);
• a copy of the ARMP was remitted to the responsible pharma-
ceutical industry, without the name of the psychiatrist who
filled out the notification, requesting more information
concerning the ARMP;
• as a next step, the reply of the pharmaceutical industry, when
received, was sent to the psychiatrist. In case the pharma-
ceutical industry requested a direct contact with the doctor,
the name and address were only furnished after gave his/
her consent.
Summing up, PSIFAVI adverse reaction notifications were
filled out by prescribing psychiatrists. There were, therefore,
spontaneous descriptions of adverse reactions made by doctors.
As a final step, each ARMP was studied by two members of
the PSIFAVI (one psychopharmacologist medical doctor and a
pharmacist) and the occasional relation of causality between
the medication and the adverse reaction was assessed, accord-
ing to the algorithm of Karch and Lasagna.16
Whenever further details to clarify the AR were needed, one
PSIFAVI member made a phone-call to the notifying doctor.
To assess whether the described ARMP was a known reaction
to the suspected agent (part of the information necessary to
establish causality), the insert package of the medication and
information from Micromedex were consulted.
Results
Two hundred and nineteen ARPMs were received between
April 1999 and September 2001. They were posted by 114 psy-
chiatrists working in 13 out of the 26 Brazilian States, what
means that several psychiatrists sent more than one ARMP. In
those 13 states, 78% of the 3.160 Brazilian psychiatrists exert
their practice. These figures represent that only 3.60% of the
contacted psychiatrists reported adverse reactions suspected of
being produced by psychoactive medications. On the other
hand, the ARPMs were notified within a 2.5-year period, mean-
ing that, on average, .069 ARPMs were notified per psychia-
trist in 2.5 years.
Gender and age of the patients suffering from adverse reac-
tions of the psychoactive medications were as follows: 42.4%
males and 57.6% females; under 19 years of age, 20.0%; 20 to
29 years, 23.0%; 30 to 39 years, 27.6%; 40 to 49 years, 10.5%;
50 to 65 years, 8.5%; above 65 years of age 9.7%; non- speci-
fied age .7%.
Of the 219 copies of ARPMs mailed to the pharmaceutical
industries, only 104 (47.5%) were answered; these responses
were sent to the notifying psychiatrists. On the other hand, the
industries requested in 8 occasions the identification of the no-
tifying doctors for further contacts; only one psychiatrist re-
fused contact with the pharmaceutical industry.
Drug adverse reactions were classified into two categories:
non-severe and severe. The latter were subclassified into the
Rev Bras Psiquiatr 2003;25(4):200-5
202
The pharmacovigilance of psychoactive medicaments
Carlini ELA & Nappo SA
Table 1 - Classification of the 219 adverse reactions to psychoactive
medications, as described by Brazilian psychiatrists during a 30 months
period (April 1999 - October 2001).
Adverse Reaction N
Not classified by the Doctor 19
Non Severe 150
Severe 50
219
Among the Severe (n=50)
Resulted in death: 3
Required/prolonged hospitalization: 26
Life-threatening: 12
Persistent/temporary disability 9
50
Table 2 - Substances responsible for the adverse reactions (total of 219 ARPMs) according to the opinion of the notifying psychiatrists.
Therapeutic Number of Substances involved
Class ARPMs Name N Name N
Antidepressants 122 Fluoxetine 24 Paroxetine 13
Venlafaxine 21 Reboxetine 13
Sertraline 17 Others 34
Neuroleptics 46 Risperidone 14 Thioridazine 5
Haloperidol 9 Olanzapine 4
Clozapine 7 Others 7
Antiepileptics 25 Phenytoin 10 Lamotrigine 4
Valproic acid 4 Oxcarbamazepine 2
Carbamazepine 4 Phenobarbital 1
Anxiolytics 8 Midazolam 2 Clonazepam 4
Bromazepam 1 Buspirone 1
Anorectics 7 Diethylpropione 3 Sibutramine 2
Fenproporex 2
Others 11
six following categories: requested or prolonged hospitaliza-
tion; life-threatening; caused temporary or permanent disabil-
ity; produced congenital anomaly; caused cancer; and death.
Table 1 shows the judgment made by psychiatrists about the
adverse reactions observed in their patients. We may note that
22.8% (50), out of 219 reported AR, were considered as severe
ones, as described below.
Three deaths (clozapine - 2; levomepromazine - 1). The first
death attributed to clozapine was a 55-year-old male schizo-
phrenic patient, who used 300 mg oral daily for 57 days and
presented a progressive leucopenia (700 counts); he was a heavy
smoker and had also a cancer in pharynx. The second clozapine
attributed death was of a 30-year-old man weighing 210 kilo-
grams; he received 600 mg by oral route and later on, in same
day, he presented myoclonic convulsion, fell on the floor, fol-
lowed by cardio-respiratory arrest. The death attributed to
levopromazine occurred in a 39-year-old schizophrenic male
patient after 26 days of oral administration of 800 mg; it was
preceded in the previous 15 hours by periods of apnea, ab-
dominal distention and finally a pulmonary edema. During the
previous month, the patient was also receiving haloperidol and
clonazepam.
Notifying doctors also classified twelve life-threatening re-
actions: neuroleptic malignant syndrome (haloperidol - 2,
olanzapine - 1); suicidal thoughts/attempts (amphepramone -
2, fluoxetine - 1, venlafaxine - 1); anaphylactic reaction (pheny-
toin - 1); leucopenia (carbamazepine - 1); myocardial infarct
(clozapine 1); glottis edema (fluoxetine - 1); Stevens-Johnson
Syndrome (haloperidol - 1).
The 26 AR reported by doctors as requiring or prolonging
hospitalization were: neuroleptic malignant syndrome
(clozapine - 1, haloperidol - 1); urinary retention (reboxetine –
1); renal stones (venlafaxine - 2); dependence syndrome (opium
- 1, fenproporex - 1); erythema (venlafaxine - 1); ‘marked skin
allergy’ (lamotrigine - 1); erythema plus fever (phenobarbital -
1), urticaria and edema of mucosa (fluoxetine - 1); muscle ri-
gidity, extrapyramidal symptoms and Parkinsonism (fluoxetine
- 1; thioridazine - 1, haloperidol - 1); pancreatitis (olanzapine -
1); hepatitis (nortriptyline - 1); hepato-renal syndrome
(venlafaxine - 1); hypertension and panic attacks(sibutramine
- 1); hypertensive crisis (milnacipran - 1; mirtazapine - 1); mania
(Hypericum perforatum - 1); tremors and allergic reaction (ami-
triptyline - 1); agitation and aggressiveness (olanzapine - 1);
psychotic crisis (sibutramine - 1); obsessive-compulsive symp-
toms (risperidone - 1) and Stevens-Johnson Syndrome
(carbamazepine - 1).
Finally, there were 9 ARPMs notifying temporary disability,
described as follows: hepatitis confirmed by laboratory data
(fluoxetine - 1); psychosis (anorectic amphetamine-like substance
- 1); muscle rigidity, ataxia and tremors (haloperidol - 1); inca-
pacitating somnolence (sertraline - 1); vomiting, ataxia and pale-
ness (periciazine - 1); parkinsonian syndrome (metoclopramide
- 1); intense spasmodic muscle contractions (risperidone - 1);
fainting and downfalls (citalopram - 1); and muscle rigidity, fe-
ver, constipation and urinary incontinence (periciazine - 1).
Table 2 summarizes all classes of substances psychiatrists
attributed to the adverse reactions. Antidepressants ranked first,
with fluoxetine ranking first, followed by venlafaxine,
sertraline, paroxetine and reboxetine. The other 34 antidepres-
sants not mentioned in Table 2 were mirtazapine, citalopram,
clomipramine, tranylcypromine, nortriptyline, bupropion,
milnacipran, fluvoxamine, nefazodone, amitriptyline and imi-
pramine.
Risperidone (14 ARPMs) was the most frequently neurolep-
tic drug cited as cause of adverse reactions, followed by halo-
peridol, clozapine, thioridazine and olanzapine.
Third, with 25 reports of ARPMs, ranked the antiepileptic
medications. Among those, there were 10 reports of reactions
caused by phenytoin; however, eight out of the 10 reactions
were reported by the same professional describing rash, pruri-
tus and other skin reactions occurring in a same hospital set-
ting, at the same occasion.
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Table 3 - Organs and systems affected by the adverse reactions produced
by psychoactive medications.
*Total number is above the 219 ARs reported, due to the fact that some of the adverse
reactions affected more than one organ/system.
Target Organ/ System/ Adverse Reaction
Apparatus Number* Percentage
Central Nervous System:
mental/ psychological 71 30.4
neural/ muscular 31 12.7
Skin and mucosal 44 19.4
Genital 16 7.0
Gastrointestinal 21 9.2
Cardiovascular 09 4.0
Renal 07 3.1
Vision 12 5.3
Hormonal 08 3.5
Fever 03 1.3
Respiratory 05 2.2
Blood 05 2.2
Total 232 100
The rather surprising small number of 8 ARPMs related to
the anxiolytic drugs was followed by seven reactions attrib-
uted to the anorectic drugs; two psychotic episodes with sui-
cidal attempts due to chronic use of amphepramone stood out
among them. All those seven cases were notified by the psy-
chiatrists as patients referred to them due to the adverse reac-
tions produced by the weight reducing medications prescribed
by other medical doctors.
Finally, among the other 11 reported adverse reactions (non-
severe), three were due to zolpidem and four were conse-
quence of phytotherapeutic medications. Among the latter, a
Passiflora incarnata suspension in 14% alcohol vehicle. The
patient, a 60 year-old woman with previous history of drug
abuse, escalated the dose of this phytomedicine because she
felt ‘happy and drunk’ as if she had actually drunk a ‘real
alcoholic beverage’.
Table 3 shows which were the target organs involved in the
adverse reactions. Psychological and neurological signs/symp-
toms related to central nervous system were the most frequently-
cited adverse reactions. Among the psychological/mental dis-
turbances stood out four cases of suicidal thoughts/attempts
(diethylpropione - 2 cases; fluoxetine - 1; venlafaxine - 1), six
patients reporting hallucinations (bromazepam - 1; nefazodone
- 1; fluvoxamine - 1; risperidone - 1; bupropion - 2), one case
of dependence (opium preparation) and two abstinence syn-
dromes (fenproporex - 1; paroxetine - 1). Psychiatrists also
notified three cases of parkinsonism (haloperidol - 1; olanzapine
- 1; thioridazine - 1), five neuroleptic malignant syndrome (ha-
loperidol - 3 cases; clozapine - 1; thioridazine - 1) and one
more possible case of neuroleptic syndrome was described by
one psychiatrist as a patient with 39°C, tetanus and autonomic
reactions (periciazine).
Skin and mucosal membrane adverse reactions were noti-
fied through 44 ARPMs; among them two reactions directly
classified by the notifying doctors as Stevens-Johnson Syn-
drome (imipramine - 1, haloperidol - 1).
Concerning the patients’ sexual functioning, anorgasmia, de-
layed ejaculation, decreased libido and priapism were described
by 16 doctors as adverse reactions produced by the psychoac-
tive medications (Table 3).
The causality analysis using the algorithm of Karch and
Lasagna16 produced the following results. In 23 cases the psy-
chiatrists reintroduced the psychoactive medication
(rechallenge), after its previous suspension (dechallenge), with
the reappearance of the adverse reaction symptomatology;
therefore, for these 23 cases there had been a Definite causal-
ity between the medication and the described AR. They were:
valproic acid - 1 AR (intense pain in epigastrium); citalopram
- 2 ARs (dysuria; erythema and pruritus); desipramine - 1 AR
(intense fatigue); fenproporex - 1 AR (dependence and with-
drawal symptoms); fluoxetine - 7 ARs (alopecia; alopecia and
acne; anorgasmia; stomach upset; tongue protrusion and swal-
lowing difficulty; visual disturbance; metrorrhagia);
lamotrigine - 1 AR (skin rash, lymphadenopathy and fatigue);
fluvoxamine - 1 AR (derealization, despersonalization and
anxiety); reboxetine - 1 AR (irritability); risperidone - 2 ARs
(constipation and apathy; acathisia and muscle spasm);
sertraline - 5 ARs (diarrhea; stomach upset; urticaria and pru-
ritus, nausea and vomiting) and thioridazine - 1 AR (orgasm
without ejaculation).
For another 134 ARs the dechallenge produced an improve-
ment of the symptomatology but the rechallenge was not per-
formed; therefore, in those cases causalities were classified as
Probable.
Twenty-five other ARs appeared in the patients after an ap-
propriate time interval between the ingestion of the medica-
tion and the occurrence of the event; moreover, they had not
been previously described for that drug and the adverse event
could not be reasonably explained through the clinical state of
the patients or due to other medications. According to Karch
and Lasagna (16), for those 25 ARs, the medications-event
causalities were classified as Conditional.
Causalities for four other ARs were classified as Possible;
and 25 ARs were considered as Not-Related, as they actually
describe lack of efficacy of the medication, or patients did not
improve after dechallenge. Finally, it was not possible to es-
tablish the causality for the last 8 remaining ARPMs.
Discussion
The present study describes 219 adverse reactions to psy-
choactive medications notified by 114 Brazilian psychiatrists
that correspond to 3.60% of the total amount of the 3,160 ones
affiliated to the Brazilian Association of Psychiatry.
Underreporting is a common feature of pharmacovigilance
all over the world with, at most, 10% of the physicians in sev-
eral countries having well-developed notifying pharma-
covigilance systems; on the other hand, in many other coun-
tries, reporting rates are much lower.17 Research projects aim-
ing to increase the reporting of suspected drug reactions have
been performed.18
It may be concluded, therefore, that the amount of AR re-
ports received is fairly acceptable taking into account that
pharmacovigilance is by no means developed in Brazil and that
ARs were notified only by psychiatrists. It is, however, sur-
prising the low level of cooperation of the pharmaceutical in-
dustry; in fact, only 47.5% of the ARPMs were commented by
Rev Bras Psiquiatr 2003;25(4):200-5
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the companies; and only 8 contacts with the notifying doctors
were requested.
Another point which may be related to the small number of
received ARs is regarding the very low number of adverse re-
actions from older and widely used psychoactive medications.
For example, there were only 1 report of AR for imipramine, 2
for amitriptyline, 5 for thioridazine, 9 for haloperidol, none for
chlorpromazine, and 8 for benzodiazepine substances (none
for diazepam). These figures contrast with the 24 AR reported
for fluoxetine, 21 for venlafaxine, and 14 for risperidone. Bra-
zilian psychiatrists are probably so used to the old psychoac-
tive substances that their attention is concentrated on the new
developments of the psychotherapeutic medications. It is as if
for Brazilian psychiatrists the reporting of adverse reactions
were a new issue and should be concerned mostly to new psy-
choactive medications.
On the other hand, if the methodology employed in this
study were applied to all other Brazilian physicians and hy-
pothesizing that the rate of their reporting would be similar
to that of psychiatrists, then nearly 19 thousands AR would
be obtained every two-year period. This is not much below
the 200 ARs per million inhabitants yearly reported in some
countries;17 with 170 million inhabitants, Brazil may have the
potential to report nearly 34,000 AR annually. Therefore, we
believe that the methodology employed in the present study
could be useful if applied thoroughly, as it may yield good
results when implanting a new system to collect AR in coun-
tries like Brazil.
Another issue that deserves further comment refers to the
quality of the reported ARs. They were obtained from patients
seen in the psychiatrists’ own private clinics (or private hospi-
tals) and, therefore, receive careful attention and follow-up. In
fact, most of the clinical descriptions of the AR fit reasonably
well into the definitions of AR established by CIOMS,19 ex-
cept for the five neuroleptic malignant syndrome cases as in
none of them the activity of creatinine phosphokinase was
measured,19 although all the cases presented hyperthermia, ri-
gidity and disturbed autonomic function.
The fact that only 23 of the 219 ARPMs (10.9%) were clas-
sified as Definite deserves attention. According to Karch &
Lasagna,16 such causality is attributed when dechallenge is fol-
lowed by rechallenge and reappearance of the AR. However,
such procedure may not be always acceptable due to safety
and ethical reasons;20 for example, it would be unacceptable to
re-expose the patients to the medications apparently causing
the 12 life-threatening adverse reactions described in this study.
Furthermore, in some other cases dechallenge is not feasible
(as in the 3 death cases) or would not function as, for example,
in cases of cataract, drug dependence, myocardial infarct, etc.,
which would not disappear with dechallenge. Therefore, the
low figure of 10.9% of ARPMs with cause and effect estab-
lished as Definite does not mean that the remaining adverse
reactions should be taken as certainly not being caused by the
medications.
Finally, 25 ARs were classified as Conditional, meaning that
they were unknown reactions to the medications. They were:
buspirone - 1 (hypotension); thioridazine - 1 (feet edema); tra-
nylcypromine - 1 (polydipsia and polyuria); paroxetine  1 (fe-
ver and joint pain); clomipramine - 1 (metrorrhagia);
sibutramine - 1 (hypomania); valproic acid  1 (macroglossia
and oral angioedema); olanzapine - 1 (leukocytosis); sertraline
- 1 (petechia); phenytoin - 1 (encopresis); cloxazolam - 1 (erec-
tile dysfunction); bromazepam - 1 (visual hallucination);
fluoxetine - 1 (glottis edema and urticaria); nefazodone - 2 (vi-
sual and auditory hallucination; sleep apnea and anxiety);
venlafaxine - 2 (spontaneous abortion; obsessive compulsive
reaction); milnacipran - 2 (pruritus; hypertension); and
reboxetine - 6 (vivid dreams; piloerection; ejaculation delay;
hematuria; hypertension; oropharynx edema and pain). Those
Conditional ARs do not mean that this study is providing 25
early warnings or signs of previously unknown adverse reac-
tions to the medications. Actually, the description of a new
adverse reaction to a drug is a complex process involving sev-
eral steps and careful scrutiny of the data.21,22 Nevertheless, we
may note that the Brazilian population differs considerably
(ethnicity; weight and height; different nutritional/environmen-
tal/social/economical conditions) from those of developed coun-
tries in which most of drug dosage schemes and description of
adverse drug reactions were produced. If this is true, further
studies on the above-described Conditional adverse reactions
and other pharmacovigilance issues in developing countries
like Brazil should be interesting.
Undoubtedly, any therapeutic process involving administra-
tion of medications has the inherent possibility of producing
undesirable adverse reactions to the patients. Taking this tru-
ism into consideration, the present study raises three points.
First, psychiatrists (as well as other medical doctors) should be
constantly reminded of that possibility and thus, advised to pre-
scribe with parsimony and in cases of real clinical necessity.
Second, the pharmaceutical industries should be obliged to
state clearly in the insert packages and promotional material
all the warnings, contra-indications and the occurrence of pos-
sible adverse reactions. Lastly, the existence of a Governmen-
tal Pharmacovigilance Service is essential, in order to collect
and disseminate to all professionals information on the occur-
rence of adverse reactions and precautions to prevent as well
as to treat them.
Needless to say that all these activities demand from psychia-
try (as well as from other medical specialties) close and constant
collaboration between medical schools, sanitary surveillance of
State and Federal Governments and specific Associations or
Societies such as the Brazilian Psychiatric Association.
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